Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revlimid in Primary Systemic Amyloidosis
NCT00166413Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Apr 2005
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in amyloid light chain amyloidosis, sponsored by Mayo Clinic. Primary endpoint: Hematologic Response Rate at 12 months. Started Apr 2005; status: completed.
02
Drugs
lenalidomide
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT00166413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00166413.